{"entity":{"id":"hdac11","kind":"target","name":"HDAC11","aka":["histone deacetylase 11","Histone deacetylase 11"],"tldr":"HDAC11 (Histone deacetylase 11) is a protein that switches other genes on and off. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma, Skin cancer and Multiple myeloma.","summary":"Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes.\n\nOpen Targets scores its association with cancer at 0.66 (direct and indirect evidence; datatypes literature 0.93, genetic association 0.38, clinical 0.95).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:19086","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19086"},{"label":"UniProt Q96DB2","url":"https://www.uniprot.org/uniprotkb/Q96DB2/entry"},{"label":"NCBI Gene 79885","url":"https://www.ncbi.nlm.nih.gov/gene/79885"},{"label":"Ensembl ENSG00000163517","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163517"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["non-hodgkin-lymphoma","skin-cancer","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.95. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"HDAC11","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:19086","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:19086","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q96DB2","url":"https://www.uniprot.org/uniprotkb/Q96DB2/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000163517","url":"https://platform.opentargets.org/target/ENSG00000163517/associations","note":"association with cancer (MONDO_0004992) 0.66; per-cancer scores at or above 0.5: plasma cell myeloma 0.55, non-Hodgkin lymphoma 0.56, skin cancer 0.56 (GraphQL API, CC0)"}],"distribution":"few-types","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA HDAC11: RNA tissue enhanced (brain 94 nTPM, testis 80 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Skin cancer (all types), Multiple myeloma); Open Targets associates it with 2 specific cancer types at or above 0.5 (plasma cell myeloma, peripheral T-cell lymphoma, not otherwise specified). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas HDAC11 tissue","url":"https://www.proteinatlas.org/ENSG00000163517-HDAC11/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000163517 associations","url":"https://platform.opentargets.org/target/ENSG00000163517/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:19086","ensembl":"ENSG00000163517","uniprot":"Q96DB2","entrez":"79885","firstDescribed":2004,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Ota et al, Nat. Genet, 2004, \"Complete sequencing and characterization of 21,243 full-length human cDNAs\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/14702039/","biology":"Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Location: Nucleus (UniProt). Locus 3p25.1 (HGNC).","whereFound":["Non-Hodgkin lymphoma: Open Targets association 0.56 with non-Hodgkin lymphoma (MONDO_0018908)","Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898)","Multiple myeloma: Open Targets association 0.55 with plasma cell myeloma (MONDO_0009693)"],"targetClass":"transcription","prevalence":[]},"route":"/targets/hdac11/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"},{"id":"skin-cancer","kind":"cancer","name":"Skin cancer (all types)","route":"/cancers/skin-cancer/"}]}}